Reviews/TNF Alpha Inhibitors/TNF-alpha inhibitors maintain steroid-free remission in ulcerative colitis
· TN-IBD-02 · v2
Across this corpus, several studies show that patients with ulcerative colitis treated with TNF-alpha inhibitors can stay in remission without needing steroids, measured at points from 16 weeks out to 2 years. The share of patients reaching this varies from roughly a fifth to a half depending on the study, so it holds for a meaningful but minority group rather than for most patients. The direction of the evidence is consistent across different trial types, which is why the panel treated the claim as well-supported. But no study here directly compared a single TNF inhibitor against a dummy treatment using the steroid-free endpoint over the maintenance period, so the cleanest form of proof is missing. The panel also noted the best single steroid-free number came from a combination with another drug, not the TNF inhibitor alone. For these reasons the evidence supports the claim qualitatively without settling it.
Four independent studies report steroid-free remission with a TNF inhibitor across the maintenance window: infliximab 22.1% at week 16 in [7], adalimumab 21.8% at week 52 in [3], infliximab 43% and adalimumab 35% at 12 months in [8], and 48% of anti-TNF withdrawal patients remaining in steroid-free remission at 2 years in [1]. [5] adds that infliximab maintenance beat placebo for clinical response at week 54 (45% vs 20%). The direction is consistent across RCT and observational designs, but the absolute steroid-free rates are a modest minority. The strongest steroid-free arm in [7] is the infliximab-plus-azathioprine combination (39.7%), not infliximab monotherapy. The contested point: The evidence divides on whether a TNF inhibitor alone drives the steroid-free maintenance effect: [7]'s best steroid-free figure comes from the azathioprine combination, [3] and [8] use active or observational comparisons, and the one placebo-controlled maintenance RCT [5] reports clinical response rather than steroid-free remission. No included trial isolates the steroid-free endpoint against placebo at maintenance.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from TNF Alpha Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No included study isolates the steroid-free endpoint against placebo at maintenance: [3] and [7] use active comparators ([7]'s strongest steroid-free arm is the azathioprine combination, confounding monotherapy attribution), [8] is observational, and the one placebo-controlled maintenance RCT [5] reports clinical response, not steroid-free remission.
Every direct steroid-free figure is a minority (22.1%–48%), so 'maintain steroid-free remission' holds for a subset of patients rather than as a general property; the unqualified claim overstates the reach of the effect.
Where it remains uncertain. The best steroid-free figure in [7] comes from the infliximab-azathioprine combination, and the only placebo-controlled maintenance RCT [5] reports clinical response, not steroid-free remission, so monotherapy attribution is unconfirmed.
Aleatory
Steroid-free remission is achieved by only a minority (22.1%-48% across [7],[3],[8],[1]), reflecting irreducible variation in who responds.
Epistemic
No included trial tests the steroid-free endpoint against placebo at maintenance; [5] is placebo-controlled but reports clinical response, not steroid-free remission.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows durable steroid-free remission under anti-TNF out to 2 years, with maintenance (96% endoscopic remission) markedly superior to withdrawal.
“Importantly, 48% of anti-TNF withdrawal patients remained in steroid-free remission.”
Panel auditInternal validity: high · scope of inference: UC patients already in deep clinical, biochemical and endoscopic remission on anti-TNF, over 2 years.Key limitations: open-label · endpoint is endoscopic remission not steroid-free specifically · majority did not receive azathioprine
Direct week-52 corticosteroid-free remission rate for adalimumab, a TNF inhibitor, in a large double-blind RCT.
Panel auditInternal validity: high · scope of inference: Adults with moderately-to-severely active UC, biologic-naive or limited prior TNF exposure, over 52 weeks.Key limitations: comparator is a non-TNF biologic, not placebo · corticosteroid-free remission CI crosses zero · no dose escalation allowed
Placebo-controlled demonstration that infliximab maintenance sustains response through week 54 in UC.
“In ACT 1, more patients who received 5 mg or 10 mg of infliximab had a clinical response at week 54 (45 percent and 44 percent, respectively) than did those who received placebo (20 percent, P<0.001 for both comparisons).”
Panel auditInternal validity: high · scope of inference: Moderate-to-severe UC despite concurrent meds, clinical response at weeks 8-54.Key limitations: endpoint is clinical response not remission · no steroid-free outcome in abstract
The abstract reports only 8-week induction clinical remission; it does not report steroid-free remission or any maintenance outcome bearing on the claim.
Panel auditInternal validity: high · scope of inference: Anti-TNF-naive UC patients failing steroids/immunosuppressants, induction at week 8.Key limitations: induction only (8 weeks) · no steroid-free remission endpoint · no maintenance data
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent direct steroid-free evidence from RCTs [3][7] and a cohort [8] out to 1-2 years supports a Likely verdict, held below Established by modest absolute rates and the absence of placebo-isolated steroid-free maintenance data.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-isolated steroid-free maintenance RCT. No included trial pits a TNF inhibitor against placebo on the steroid-free endpoint over the maintenance window; [5] used placebo but measured clinical response. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized, placebo-controlled maintenance trial of TNF-inhibitor monotherapy with corticosteroid-free remission as the pre-specified maintenance endpoint.
Open question: Does a TNF inhibitor as monotherapy maintain steroid-free remission better than placebo over the maintenance window in ulcerative colitis? Why it is still open: No included study isolates the steroid-free endpoint against placebo at maintenance; the placebo-controlled RCT [5] reports clinical response only.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19